Innovative Pharmaceutical Biotech Beheer

Beheer criteriumcontroles 2/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	8.9yrs
Gemiddelde ambtstermijn bestuur	13yrs

Recente managementupdates

Recent updates

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Aug 12

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

Jan 05

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Feb 18

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Nov 26

CEO

Innovative Pharmaceutical Biotech heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rong Tang	Executive Director	10.2yrs	HK$548.00k	0.022% HK$ 80.8k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	geen gegevens
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	geen gegevens
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	4.2yrs	geen gegevens	28.87% HK$ 107.3m
Hon Yin Poon	Financial Controller & Company Secretary	11.5yrs	geen gegevens	geen gegevens
Qi Dong	Sales Head of the Group	no data	geen gegevens	geen gegevens
Wei Yu	Joint Chairman to the Department of Innovation & Strategic Development and Advisor	no data	geen gegevens	geen gegevens
Jie Gu	Adviser and Joint Chairman to the Department of Innovation & Strategic Development	8.9yrs	geen gegevens	geen gegevens
Yi Xie	Chief Executive of United Gane Holdings Limited	no data	geen gegevens	geen gegevens
Dong Hui	General Manager of the Group and Director of CJV	no data	geen gegevens	geen gegevens

8.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: 399's management team is seasoned and experienced (8.9 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rong Tang	Executive Director	10.2yrs	HK$548.00k	0.022% HK$ 80.8k
Yuan Xing Gao	Executive Director	8.8yrs	HK$1.36m	geen gegevens
Tak Yiu Cheng	Executive director	1.3yrs	HK$90.00k	geen gegevens
Yumin Mao	Honorary Chairman & Chief Scientific Adviser	14.2yrs	geen gegevens	28.87% HK$ 107.3m
Dong Hui	General Manager of the Group and Director of CJV	no data	geen gegevens	geen gegevens
Chung Lau	Director of CJV	no data	geen gegevens	geen gegevens
Weijun Chen	Independent Non-Executive Director	15yrs	HK$80.00k	geen gegevens
Nian Jiang	Non Executive Chairman	13.9yrs	HK$60.00k	geen gegevens
Yanmin Wu	Non-Executive Director	13.4yrs	HK$60.00k	geen gegevens
Rongliang Wang	Independent Non-Executive Director	13.4yrs	HK$60.00k	geen gegevens
Yan Xiao	Non-Executive Director	12.5yrs	HK$60.00k	geen gegevens
Jinzhong Chen	Independent Non-Executive Director	3.8yrs	HK$60.00k	geen gegevens

13.0yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: 399's board of directors are seasoned and experienced ( 13 years average tenure).

Innovative Pharmaceutical Biotech Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Less than half of directors are independent

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 29, 2024

New minor risk - Share price stability

Full year 2024 earnings released: EPS: HK$0.068 (vs HK$0.17 loss in FY 2023)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2024 Results on Jun 28, 2024

Innovative Pharmaceutical Biotech Limited has filed a Follow-on Equity Offering in the amount of HKD 19.95 million.

First half 2024 earnings released: EPS: HK$0.13 (vs HK$0.079 loss in 1H 2023)

New major risk - Financial position

Innovative Pharmaceutical Biotech Limited Provides Unaudited Earnings Guidance for the Six Months Ended 30 September 2023

Innovative Pharmaceutical Biotech Limited to Report First Half, 2024 Results on Nov 29, 2023

Innovative Pharmaceutical Biotech Limited (SEHK:399) entered into a memorandum of understanding to acquire a majority interest in Niraxx Light Therapeutics, Inc.

New minor risk - Share price stability

Innovative Pharmaceutical Biotech (HKG:399) Has Debt But No Earnings; Should You Worry?

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2023

Innovative Pharmaceutical Biotech Limited Appoints Cheng Tak Yiu as an Executive Director

Full year 2023 earnings released: HK$0.17 loss per share (vs HK$0.031 profit in FY 2022)

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2023

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

First half 2023 earnings released: HK$0.079 loss per share (vs HK$0.085 profit in 1H 2022)

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending 30 September 2022

Innovative Pharmaceutical Biotech Limited to Report First Half, 2023 Results on Nov 29, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: HK$0.031 (vs HK$0.14 loss in FY 2021)

Innovative Pharmaceutical Biotech Limited, Annual General Meeting, Aug 30, 2022

Innovative Pharmaceutical Biotech Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released

Innovative Pharmaceutical Biotech Limited to Report Fiscal Year 2023 Results on Jun 29, 2022

Less than half of directors are independent

Robust Earnings May Not Tell The Whole Story For Innovative Pharmaceutical Biotech (HKG:399)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Innovative Pharmaceutical Biotech Limited Provides Earnings Guidance for the Six Months Ending September 30, 2021

Full year 2021 earnings released: HK$0.14 loss per share (vs HK$0.14 loss in FY 2020)

New 90-day high: HK$0.28

Is Innovative Pharmaceutical Biotech (HKG:399) Using Too Much Debt?

Innovative Pharmaceutical Biotech Limited Announces Executive Changes

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.064 loss per share

Innovative Pharmaceutical Biotech's(HKG:399) Share Price Is Down 80% Over The Past Five Years.

Innovative Pharmaceutical Biotech Limited to Report First Half, 2021 Results on Nov 27, 2020

Innovative Pharmaceutical Biotech Limited Announces Board Changes

New 90-day high: HK$0.27

New 90-day high - HK$0.26

Mao Yumin completed the acquisition of 19.14% stake in Extrawell Pharmaceutical Holdings Limited (SEHK:858) from Innovative Pharmaceutical Biotech Limited (SEHK:399).

Full year earnings released - HK$0.14 loss per share

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd